[go: up one dir, main page]

EP2049164A2 - Procédé de traitement de plaies de la peau - Google Patents

Procédé de traitement de plaies de la peau

Info

Publication number
EP2049164A2
EP2049164A2 EP07804721A EP07804721A EP2049164A2 EP 2049164 A2 EP2049164 A2 EP 2049164A2 EP 07804721 A EP07804721 A EP 07804721A EP 07804721 A EP07804721 A EP 07804721A EP 2049164 A2 EP2049164 A2 EP 2049164A2
Authority
EP
European Patent Office
Prior art keywords
skin
wound
gingival fibroblasts
fibroblasts
keratinocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07804721A
Other languages
German (de)
English (en)
Other versions
EP2049164B1 (fr
Inventor
Bruno Gogly
Bernard Coulomb
Antoine Lafont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Original Assignee
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Descartes filed Critical Universite Paris Descartes
Publication of EP2049164A2 publication Critical patent/EP2049164A2/fr
Application granted granted Critical
Publication of EP2049164B1 publication Critical patent/EP2049164B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F15/00—Auxiliary appliances for wound dressings; Dispensing containers for dressings or bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00365—Plasters use
    • A61F2013/00519—Plasters use for treating burn
    • A61F2013/00527—Plasters use for treating burn artificial skin

Definitions

  • the present invention relates to a method for treating skin wounds, in particular by promoting or accelerating skin wound healing.
  • Skin is a large organ, crucial for life, which protects the organism against environmental stresses, such as physical, chemical and mechanical stresses, and which prevents water loss.
  • the complexity of skin notably arises from the association various tissues having different embryologic origins. While the barrier functions of skin depend on the epidermis, through the differentiation process of keratinocytes, skin homeostasis depends on the balance of multiple cellular and tissular interactions in which the dermis plays a key role.
  • Wound healing is a complex and dynamic process involving soluble mediators, blood cells, extracellular matrix components, and resident cells, including fibroblasts.
  • the wound healing process includes three interactive phases: inflammation, granulation tissue formation and remodelling. This sequence of events aims at the recovering of tissue integrity and the restoration of its functions.
  • the quality of the healing - which should ideally lead to an absence of scar and to the reestablishment of tissular function - is thus depending on a complex equilibrium.
  • the fetus In many species, the fetus possesses the unique ability to heal skin wounds without scar formation (Estes et al. (1994) Differentiation 56:173; Ferguson et al. (1996) Plast. Reconstr. Surg. 97:854), nevertheless adults will always present aftereffects that can lead to functional disorders.
  • a disturbance in wound healing may also be characterized by poor healing or an absence of healing, as is notably observed in diabetes, and pressure, arterial or venous ulcers. Hypertrophic scars and contraction features following burn wounds lead to functional troubles.
  • the treatment for such wounds generally consists in the use of compressive dressings that will have to be kept during months or years. In most cases additional surgical operations will be necessary.
  • grafting of cells or grafting of in vitro reconstructed tissues appears to be a promising field in the treatment of skin wounds.
  • the minimum requirement is to reestablish a barrier function to avoid infection and water loss. It is the horny layer of the epidermis (the product of terminal keratinocyte differentiation) that plays this role.
  • the barrier function depends on the epidermis, there is also a need to improve grafting by incorporating dermal tissue in order to promote the functionality of the engrafted zone.
  • Dermis neo-formation is an important step in wound healing since dermis accounts for a number of the mechanical properties of skin and promotes the formation and anchoring of a neo-epidermis, in particular through the activation of growth and differentiation of keratinocytes.
  • Dermal fibroblast grafting in the frame of the management of skin wounds has been shown to accelerate the formation of a neo-dermis and to improve the functionality of the grafted area (Coulomb et a/. (1998) Plast. Reconstr. Surg. 101 :1891-1903). This is notably due to the promotion of the synthesis of elastin which contributes to the mechanical properties of the skin. This improvement in dermis directly impacts on the organization and anchorage of epidermis.
  • a normal undulated dermo-epidermal junction is formed within one year of dermal fibroblast grafting in a skin wound whereas, in the absence of such a grafting, from 3 (in children) to 5 years (in adults) are required to obtained the same result.
  • fibroblasts of the adipose tissue although being similar to dermal fibroblasts in many respects (van der Bogaerdt et al. (2002) Arch. Dermatol. Res.
  • Gingival fibroblasts are mesenchymal cells which are capable of migrating, adhering and proliferating within the soft connective tissues of the gum, thereby maintaining the integrity of the gingival tissue which is exposed to numerous aggressions, such as mechanical stresses, bacterial infections, or pH and temperature variations. Gingival fibroblasts are in particular described in Gogly et al., (1997) Clin. Oral Invest. 1 :147-152; Gogly et al. (1998) Biochem. Pharmacol. 56:1447-1454; and Ejeil et al. (2003) J. Periodontol. 74:188-195.
  • gingival fibroblasts are capable to modulate their phenotype, and to respond by proliferating, migrating, synthesising matrix components or matrix-related enzymes.
  • Gingival fibroblasts synthesise collagens (e.g. types I, III, V, Vl, VII, XII) elastic fibers (oxytalan, elaunin and elastin), proteoglycans and glycosaminoglycans (e.g. decorin, biglycan), glycoproteins (e.g. fibronectin, tenascin).
  • gingival fibroblasts synthesise enzymes that are able to degrade the macromolecular compounds (matrix metelloproteinases; MMPs), but also enzymes inhibiting active forms of MMPs (Inhibitors of metalloproteinases; TIMPs). Gingival fibroblasts are thus important actors of extracellular matrix remodelling.
  • the present invention arises from the unexpected finding by the present Inventors that gingival fibroblasts could advantageously replace dermal fibroblasts in promoting the formation of a dermis in skin wounds.
  • the present invention relates to a method for treating a skin wound in an individual, comprising applying to the skin wound a therapeutically effective quantity of gingival fibroblasts.
  • the present application also relates to the use of gingival fibroblasts for the manufacture of a medicament intended for treating a skin wound.
  • keratinocytes are also applied to the skin wound.
  • At least one wound healing-activating compound is administered to the individual.
  • gingival fibroblasts are easily sampled and cultured. Besides, gingival fibroblasts possess a high expansion rate.
  • the gingival fibroblasts used in the method according to the invention are autologous, that is they are taken from the individual to the wounds of which they are intended to be applied.
  • the individual is a mammal and more preferably a human.
  • the gingival fibroblasts can also be allogenic, that is taken from another individual of the same species or heterologous, that is taken from another individual of another species.
  • gingival fibroblasts provide for an almost limitless source of autologous fibroblasts. Furthermore, in case of large burns, autologous gingival fibroblasts are usually still available, whereas, in contrast, sources of autologous dermal fibroblasts are scarce.
  • a "skin wound” relates to any rupture of the epidermis and/or the dermis.
  • Skin wounds according to the invention can be particularly selected from the group consisting of chronic wounds, pressure ulcers, venous ulcers, or skin burns.
  • skin wounds according to the invention can also be surgical wounds, i.e. wounds voluntarily made during a surgical procedure.
  • surgical wounds notably encompass wounds occurring in the course of plastic and reconstructive surgery or scar revision wounds (e.g. hypertrophic scars).
  • the plastic and reconstructive surgery procedures according to the invention can be of any type, e.g. breast surgery, abdominal surgery, nose surgery, ear surgery, or removal of skin defects.
  • skin defects relate to an abnormal skin formation found in genetically predisposed individuals, or to the consequences of an abnormal skin development during embryogenesis, and notably comprise giant naevi, cheiloschisis, and keloids.
  • treating a skin wound relates to the promotion, the acceleration, or the improvement of healing at the wounded site, i.e. the formation of a functional skin at the wounded site, and/or to the application of a gingival fibroblast-based functional skin substitute at the wounded site.
  • a "functional skin” relates to skin having in particular recovered its mechanical properties and its barrier function, with respect to non- wounded skin areas.
  • applying relates to the contacting or the grafting of gingival fibroblasts onto exposed tissues at the wound site.
  • the contacting or the grafting of the gingival fibroblasts onto exposed tissues at the wound site can be carried out according to any technique known the person skilled in the art.
  • the gingival fibroblasts can be directly deposited in the wound as a liquid or gel cell suspension, as a spray, or as a cell culture on a gel or solid medium.
  • the cell culture of gingival fibroblasts is in a monolayer or tri- dimensional (3D) form.
  • the cell culture can be a biocompatible lattice seeded and/or colonized by gingival fibroblasts.
  • a biocompatible lattice preferably relates to a lattice which does not induce rejection from the organism it is implanted in. More preferably a biocompatible lattice relates to a lattice which does not induce the formation of fibrosis. It is preferred that the biocompatible lattice used is bioresorbable, that is spontaneously degraded by the organism in which it is implanted, preferably after the lattice is no more useful for the cell culture.
  • the biocompatible lattice is made of one or several biopolymers, i.e. polymers which comprise at least one unit which can be found in living organisms.
  • Materials for the constitution of the biocompatible lattice can in particular be selected from the group constituted of collagen, proteoglycan, fibrin, and chitin.
  • Collagen Type I is preferred in the frame of the present invention, given its biocompatible and bioresorbable properties. Besides, the use of collagen is also advantageous since it can modulate fibroblast phenotype and promote an in vivo- like behaviour, in particular as regards differentiation, as described by Nusgens et al. (1984) Collagen ReI. Res. 4:351-364.
  • Lattices seeded and/or colonized by gingival fibroblast are designated as dermal equivalents in the Examples.
  • General procedures for the implementation and implantation in skin wounds of dermal equivalents comprising gingival fibroblasts can be easily derived from Coulomb et al. (1998) Plast. Reconstr. Surg.
  • the quantities of gingival fibroblasts to be applied to the wounds can be easily determined by the person skilled in the art depending on the mode of application.
  • approximately 8 x 10 6 individual gingival fibroblasts can be used to seed the lattice.
  • Keratinocytes are epidermal cells well known to the man skilled in the art which constitute the epidermis.
  • Keratinocytes used in the method according to the invention can be applied as individual cells or as cell cultures or tissue samples, such as skin biopsies. As intended herein the keratinocytes can be applied prior to, simultaneously, and/or subsequently to gingival fibroblasts.
  • the keratinocytes can be directly applied to the wound once the gingival fibroblasts have been applied.
  • the keratinocytes can be applied to the wound as a culture of cells grown on a culture of gingival fibroblasts.
  • keratinocytes are added thereon to form a skin equivalent in situ.
  • a skin equivalent is prepared ex vivo by culturing keratinocytes onto a dermal equivalent and the whole skin equivalent is subsequently applied to the wound.
  • the keratinocytes used in the method according to the invention are autologous, that is they are taken from the individual to the wounds of which they are intended to be applied.
  • the individual is mammal and more preferably a human.
  • the keratinocytes can also be allogenic, that is taken from another individual of the same species or heterologous, that is taken from another individual of another species.
  • Keratinocyte are useful for the acceleration, or the improvement of healing at the wounded site, i.e. the formation of a functional skin at the wounded site, however they are particularly advantageous where application of a gingival fibroblast-based functional skin substitute at the wounded site is sought. In the latter case, it is preferred that the keratinocytes are autologous.
  • Wound healing-activating compound relates to any compound which has the ability to promote, accelerate, or improve skin wound healing.
  • Such compounds are preferably selected from the group constituted of growth factors and cytokines.
  • such compounds can be administered prior to, simultaneously, and/or subsequently to the application of the gingival fibroblasts.
  • the compounds can be administered by various administration routes such as the oral, intra-venous, intra-muscular, or sub-cutaneous route. Alternatively, the compounds can also be directly applied to the wound.
  • Fibroblasts are recovered from biopsies either by using enzymatic treatment of the tissue sample or by migration of cells from tissue samples that have been placed to adhere on a cell culture substrate, in particular as described in N Weg et al. (2006) J. Periodontol. 77:238-47. Fibroblasts are then expanded on adapted culture media according to techniques well-known to the man skilled in the art.
  • Gingival fibroblasts as obtained according to Example 1 are cultured in the presence of a tri-dimensional collagen lattice according to general procedures, such as the one described in Coulomb et al. (1998) Plast Reconstr. Surg. 101 :1891-1903 until the collagen fibrils of the lattice are contracted by the gingival fibroblasts to form a tissue-like structure, the dermal equivalent.
  • the dermal equivalent is typically obtained after approximately 1 or 2 weeks of culture. Preliminary results obtained by the Inventors indicate that gingival fibroblasts are more efficient than dermal fibroblasts in promoting tissue remodelling.
  • Example 3 In vitro reconstruction of a skin equivalent: Evaluation of epidermalization promotion
  • a two-layered skin equivalent (epidermis + dermis) is produced by applying calibrated cutaneous biopsies obtained as described in Coulomb et al (1986) Br. J. Dermatol. 4:157-168 as epidermal source, on a dermal equivalent constructed as described in Example 2.
  • This method is suitable for quantitatively evaluating epidermal formation by measuring epidermal surface. Epidermal formation is compared for dermal equivalents obtained with dermal fibroblasts (control) and gingival fibroblasts. Preliminary results indicate that gingival fibroblasts are more efficient than dermal fibroblasts for promoting the growth and differentiation of an epidermis.
  • Example 4 In vivo wound healing: Evaluation of wound closure promotion
  • Rats are wounded by three muscle-deep cuts into which are respectively applied a control un-colonized collagen lattice, a dermal equivalent obtained with dermal fibroblasts and a dermal equivalent obtained with gingival fibroblasts (Example 2). Wound healing speed and quality are monitored.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un procédé de traitement d'une plaie de la peau chez un être humain, comportant l'application sur la plaie de la peau de l'être humain d'une quantité thérapeutiquement efficace de fibroblastes gingivaux.
EP07804721.4A 2006-08-10 2007-08-07 Procédé de traitement de plaies de la peau Active EP2049164B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83667106P 2006-08-10 2006-08-10
PCT/IB2007/002264 WO2008017927A2 (fr) 2006-08-10 2007-08-07 Procédé de traitement de plaies de la peau

Publications (2)

Publication Number Publication Date
EP2049164A2 true EP2049164A2 (fr) 2009-04-22
EP2049164B1 EP2049164B1 (fr) 2017-12-27

Family

ID=38786997

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07804721.4A Active EP2049164B1 (fr) 2006-08-10 2007-08-07 Procédé de traitement de plaies de la peau

Country Status (6)

Country Link
US (1) US8303948B2 (fr)
EP (1) EP2049164B1 (fr)
JP (1) JP2010500335A (fr)
CA (1) CA2660434C (fr)
ES (1) ES2663690T3 (fr)
WO (1) WO2008017927A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526585A (ja) * 2008-03-31 2011-10-13 スカルセル テラピュティク 皮膚の老化の美容的処置法
US20120100111A1 (en) * 2009-03-06 2012-04-26 Universite Paris Descartes Method for treating cancer
EP2474610B1 (fr) * 2009-08-31 2016-08-03 Osaka University Méthode de production efficace de cellules souches pluripotentes induites au moyen de cellules dérivées de la gencive
FR2953723B1 (fr) * 2009-12-11 2012-02-24 Scarcell Therapeutics Composition pharmaceutique destinee au traitement des pathologies orthopediques
FR3008316B1 (fr) 2013-07-09 2020-01-31 Assistance Publique - Hopitaux De Paris Utilisation de fibroblastes gingivaux dans le traitement de l'alopecie
CN105852806B (zh) * 2016-03-24 2018-07-31 浙江大学 一种用于伤口实时监测的电子皮肤
US11229670B2 (en) 2016-11-18 2022-01-25 Scarcell Therapeutics Compositions useful for the treatment of immune-related diseases
US12297454B2 (en) 2023-03-15 2025-05-13 Scarcell Technologies Mammalian cell population and medicaments for cell therapies in canines and improved cell cultivation methods
WO2024189522A1 (fr) 2023-03-15 2024-09-19 Scarcell Therapeutics Population de cellules de mammifère et médicaments pour thérapies cellulaires chez des mammifères et procédés de culture cellulaire améliorés

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59501298A (ja) * 1982-05-26 1984-07-26 マサチュ−セッツ・インステチュ−ト・オブ・テクノロジ− 骨同等物およびその製造法
US5891558A (en) * 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
WO2001082773A2 (fr) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures utiles dans le genie osseux et procedes
DE10127933A1 (de) * 2001-06-08 2002-12-12 Universitaetsklinikum Freiburg Transplantat zur Abdeckung von Defekten in der Mundhöhle
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
US7775965B2 (en) 2004-03-09 2010-08-17 The Board Of Regents Of The University Of Oklahoma Decellularized grafts from umbilical cord vessels and process for preparing and using same
FR2872431B1 (fr) * 2004-07-02 2007-07-20 Univ Rene Descartes Paris V Et Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008017927A2 *

Also Published As

Publication number Publication date
CA2660434A1 (fr) 2008-02-14
CA2660434C (fr) 2016-09-27
WO2008017927A2 (fr) 2008-02-14
EP2049164B1 (fr) 2017-12-27
US8303948B2 (en) 2012-11-06
US20100166711A1 (en) 2010-07-01
JP2010500335A (ja) 2010-01-07
ES2663690T3 (es) 2018-04-16
WO2008017927A3 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
US8303948B2 (en) Method for treating skin wounds
Dreifke et al. Current wound healing procedures and potential care
MacNeil Biomaterials for tissue engineering of skin
Galassi et al. In vitro reconstructed dermis implanted in human wounds: degradation studies of the HA-based supporting scaffold
Bhardwaj et al. 3D functional scaffolds for skin tissue engineering
CN101361990B (zh) 一种双层人工皮肤及其制备方法
JP2008207002A (ja) 組織修復用支持マトリックス上の細胞
JP2019513514A (ja) 複合細胞外マトリックス成分生体材料
CN108409938A (zh) 一种新型可降解聚氨酯生物材料及其制备方法和应用
JP2002526204A (ja) 中和キトサンスポンジまたは中和キトサン／コラーゲン混合スポンジを用いる人工真皮構造物
CN101595211A (zh) 皮肤替代物及其制备方法与用途
KR20210105252A (ko) 수축 제어가 가능한 진피층 개발, 및 이를 이용한 균일한 성능의 인공피부 의 제조
JP5454980B2 (ja) 間葉系細胞増殖促進剤およびそれを含有する骨格系生体材料
KR20010072553A (ko) 살아있는 키메릭 피부 대체물
JP5478885B2 (ja) 組織の再構築のために特に有用な、生体適合性で且つ生分解性の多孔質マトリックス
JP3333108B2 (ja) 上皮性組織移植片およびその製造方法
Mathias‐Santamaria et al. Silk‐fibroin chitosan film for palatal wounds: Material development, in vitro study, and pilot clinical trial
US20020001623A1 (en) Organism-compatible materials with combined extra-cellular matrices, extracellular-matrix preparations, and production methods
JPWO2003009783A1 (ja) 角膜治療用積層体及びその製造方法
JP3105308B2 (ja) 人工皮膚およびその製造法
RU2644306C1 (ru) Способ восстановления дефектов покровных тканей
GB2365443A (en) Bioabsorbable matrix for use as surgical/medical dressing
JP2002065247A (ja) 細胞培養基材
RU2852683C1 (ru) Способ регионарного лечения хронических ран
WO2018056798A1 (fr) Procédé de préparation d'un tissu à partir de cultures de cellules mésenchymateuses de gélatine de wharton et utilisations de ce dernier

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090506

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Owner name: UNIVERSITE RENE DESCARTES (PARIS V)

Owner name: INSERM

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Owner name: INSERM

Owner name: UNIVERSITE PARIS DESCARTES

111L Licence recorded

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC MT NL PL PT RO SE SI SK TR

Free format text: EXCLUSIVE LICENSE

Name of requester: SCARCELL THERAPEUTICS, FR

Effective date: 20110107

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170320

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

INTC Intention to grant announced (deleted)
GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

111L Licence recorded

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC MT NL PL PT RO SE SI SK TR

Free format text: EXCLUSIVE LICENSE

Name of requester: SCARCELL THERAPEUTICS, FR

Effective date: 20110107

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

INTG Intention to grant announced

Effective date: 20171117

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: PK

Free format text: ERGAENZUNG LIZENZEINTRAG: AUSSCHLIESSLICHE LIZENZ

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 957760

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007053553

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2663690

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20171227

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 957760

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180427

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007053553

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

26N No opposition filed

Effective date: 20180928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220113 AND 20220119

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: UNIVERSITE PARIS CITE, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE PARIS DESCARTES, PARIS, FR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: UNIVERSITE DE PARIS, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE PARIS DESCARTES, PARIS, FR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: INSERM, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE PARIS DESCARTES, PARIS, FR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE PARIS DESCARTES, PARIS, FR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: UNIVERSITE PARIS CITE, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE DE PARIS, PARIS, FR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: INSERM, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE DE PARIS, PARIS, FR

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007053553

Country of ref document: DE

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, FR

Free format text: FORMER OWNERS: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PARIS, FR; INSERM, PARIS, FR; UNIVERSITE DE PARIS, PARIS, FR

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: UNIVERSITE DE PARIS

Effective date: 20221216

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: UNIVERSITE PARIS CITE

Effective date: 20230214

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250925

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250820

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20250825

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250820

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250829

Year of fee payment: 19